Related references
Note: Only part of the references are listed.Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial
M. Reck et al.
ANNALS OF ONCOLOGY (2013)
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
S. F. Slovin et al.
ANNALS OF ONCOLOGY (2013)
Vemurafenib in melanoma
Heather M. Shaw et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2013)
Tremelimumab: a review of development to date in solid tumors
Ahmad A. Tarhini
IMMUNOTHERAPY (2013)
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Patient Responses to Ipilimumab, a Novel Immunopotentiator for Metastatic Melanoma How Different are these From Conventional Treatment Responses?
Gregory K. Pennock et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2012)
Immuno-oncology: understanding the function and dysfunction of the immune system in cancer
O. J. Finn
ANNALS OF ONCOLOGY (2012)
Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab
Vafa Shahabi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
Peter A. Prieto et al.
CLINICAL CANCER RESEARCH (2012)
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Thomas J. Lynch et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Jeffrey S. Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma
Jeffrey S. Weber et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
Anna Maria Di Giacomo et al.
LANCET ONCOLOGY (2012)
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Kim Margolin et al.
LANCET ONCOLOGY (2012)
Two Hundred Years of Cancer Research
Vincent T. DeVita et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Raising the Bar: The Curative Potential of Human Cancer Immunotherapy
Steven A. Rosenberg
SCIENCE TRANSLATIONAL MEDICINE (2012)
The confluence of radiotherapy and immunotherapy
Byron Bumette et al.
FRONTIERS IN ONCOLOGY (2012)
Current and future adjuvant immunotherapies for melanoma: Blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach
Sanjiv S. Agarwala et al.
CANCER TREATMENT REVIEWS (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
New drugs in melanoma: It's a whole new world
Alexander M. M. Eggermont et al.
EUROPEAN JOURNAL OF CANCER (2011)
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma
Evan M. Hersh et al.
INVESTIGATIONAL NEW DRUGS (2011)
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Omid Hamid et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
A methodological framework to enhance the clinical success of cancer immunotherapy
Axel Hoos et al.
NATURE BIOTECHNOLOGY (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
Claus Garbe et al.
ONCOLOGIST (2011)
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
Padmanee Sharma et al.
NATURE REVIEWS CANCER (2011)
Advances in systemic treatment of melanoma
A. M. M. Eggermont
ANNALS OF ONCOLOGY (2010)
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
S. J. O'Day et al.
ANNALS OF ONCOLOGY (2010)
Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Improved Endpoints for Cancer Immunotherapy Trials
Axel Hoos et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok et al.
LANCET ONCOLOGY (2010)
Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma
Sanjiv S. Agarwala
MELANOMA RESEARCH (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy
Axel Hoos et al.
SEMINARS IN ONCOLOGY (2010)
Update on Immunologic Therapy With Anti-CTLA-4 Antibodies in Melanoma: Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their Management
Katharina C. Kaehler et al.
SEMINARS IN ONCOLOGY (2010)
CTLA-4 blockade: therapeutic potential in cancer treatments
Ahmad Tarhini
OncoTargets and Therapy (2010)
Cancer Prevention: From 1727 to Milestones of the Past 100 Years
Scott M. Lippman et al.
CANCER RESEARCH (2009)
Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy?
Antoni Ribas et al.
CLINICAL CANCER RESEARCH (2009)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Jeffrey Weber et al.
CLINICAL CANCER RESEARCH (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
Shawn D. Blackburn et al.
NATURE IMMUNOLOGY (2009)
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials
Edward L. Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Molecular origins of cancer - Cancer immunology
Olivera J. Finn
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Radiotherapy augments the immune response to prostate cancer in a time-dependent manner
Timothy J. Harris et al.
PROSTATE (2008)
Tumor immunoediting and immunosculpting pathways to cancer progression
Jennifer M. Reiman et al.
SEMINARS IN CANCER BIOLOGY (2007)
Immunostimulatory monoclonal antibodies for cancer therapy
Ignacio Melero et al.
NATURE REVIEWS CANCER (2007)
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
KS Peggs et al.
CURRENT OPINION IN IMMUNOLOGY (2006)
Paradoxical roles of the immune system during cancer development
KE de Visser et al.
NATURE REVIEWS CANCER (2006)
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study
AV Maker et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
P Attia et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Regulation of tumor progression by anti-neoplastic T cell responses
SI Abrams
CANCER BIOLOGY & THERAPY (2004)
Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
AMM Eggermont et al.
EUROPEAN JOURNAL OF CANCER (2004)
Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques
T Keler et al.
JOURNAL OF IMMUNOLOGY (2003)
Immunotherapy: past, present and future
TA Waldmann
NATURE MEDICINE (2003)
Share Paper
